Cardiovascular Drug Innovation: 5 Paths for 2026
New heart drug discovery faced challenges. See 5 ways AI and organoids are speeding up R&D, impacting patients like Dr. Sharma's father.
New heart drug discovery faced challenges. See 5 ways AI and organoids are speeding up R&D, impacting patients like Dr. Sharma's father.
Novartis's Lp(a) drug failure leaves 80% undiagnosed. What went wrong, and what new treatments are on the horizon for 2026?
Pelacarsen failed its 2025 trial. Does this end Lp(a) drug research for heart disease? See why new siRNA drugs offer hope for high Lp(a).
AI financial tools show a 3.5% higher error rate for minorities. Learn why this matters for your investments and what SEC rules are coming.
Pelacarsen cut Lp(a) by 80%, but lacked MACE proof. This shifts drug trials to direct clinical benefits, not just biomarkers, for heart disease. What's next
Lp(a) drug development faces hurdles. See why new therapies like ASOs are changing cardiovascular care and what to watch for by 2026.
New therapies are targeting Lp(a), a genetic heart risk. Learn about 80% reductions in trials, ESC guidelines, and what's next for patients.
Pelacarsen's Phase 3 failure delays Lp(a) drug development until 2026. Why Novartis and Ionis's trial results matter for heart disease patients.
Will Panama become the Americas' nearshoring hub? See how its logistics and Colón Free Zone growth, projected at 15% by 2026, shape its role.
New drugs target Lp(a), a genetic heart risk affecting 1 in 5 people. Will they gain approval, and how will pricing impact a potential $1.4B market?